fosaprepitant / Generic mfg. - LARVOL DELTA

Comparison of aprepitant 80 mg oral, aprepitant 32.4 mg intravenous, and fosaprepitant 75 mg intravenous in the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic sleeve gastrectomy, a retrospective cohort study. (PubMed, Surg Endosc) - "In this retrospective cohort, fosaprepitant 75 mg IV was found to be superior overall to aprepitant 32.4 mg IV and 80 mg PO."

Journal • Retrospective data • Anesthesia • Gastrointestinal Disorder • Pain

Cost-effectiveness analysis of fosaprepitant versus aprepitant-based antiemetic regimens in children receiving highly emetogenic chemotherapy: individual patient-level analysis of a randomised trial. (PubMed, BMJ Support Palliat Care) - "Intravenous fosaprepitant, administered in combination with ondansetron and dexamethasone, was not cost-effective compared with oral aprepitant-based combination therapy in India but demonstrated cost-effectiveness in the USA."

HEOR • Journal • Oncology • Pediatrics

Perioperative Fosaprepitant Use Prior to Suspected Coronary Artery Vasospasm (ASA 2026) - "Bedside ECG revealed ST elevations in inferior leads with reciprocal changes in the anterolateral leads. She underwent emergent left heart catheterization that was negative for coronary stenosis, with possible coronary artery spasm related to fosaprepitant."

Cardiovascular • Dyslipidemia • Endocrine Disorders • Genetic Disorders • Hypertension • Hypotension • Obesity

Dexamethasone-Free Antiemetic Prophylaxis for Children and Adolescents Receiving Highly Emetogenic Chemotherapy: A Multicenter, Phase III, Noninferiority Trial (CIVIC POD). (PubMed, J Clin Oncol) - "A dexamethasone-free regimen using olanzapine demonstrated noninferior control of vomiting compared with standard prophylaxis in children and adolescents receiving HEC, supporting olanzapine as a potential corticosteroid-sparing alternative for pediatric CINV prophylaxis."

Head-to-Head • Journal • P3 data • Chemotherapy-Induced Nausea and Vomiting • Pediatrics

Aprepitant and Fosaprepitant for Preventing Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy-A Real-World Study. (PubMed, Curr Oncol) - "In this prospective, non-randomized observational study, we compared the efficacy of oral aprepitant and intravenous fosaprepitant administered in combination with 5-hydroxytryptamine-3 receptor antagonists and dexamethasone in 136 chemotherapy-naive patients receiving cisplatin- or doxorubicin-cyclophosphamide-based regimens. These findings indicate that no statistically significant differences in antiemetic efficacy were observed between aprepitant and fosaprepitant in routine clinical practice. Fosaprepitant may therefore represent a practical alternative when oral administration is not feasible."

Journal • Observational data • Real-world evidence • Chemotherapy-Induced Nausea and Vomiting

BARF RCT: Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide (clinicaltrials.gov) - P4 | N=212 | Not yet recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Feb 2027 ➔ Sep 2027 | Trial primary completion date: Feb 2027 ➔ Sep 2027

Trial completion date • Trial primary completion date

A scoping review on vascular complications in breast cancer patients receiving anthracycline-based anticancer drugs. (JBCS 2026) - "Drug-related factors identified included the use of liquid formulations, increased dose and frequency of anticancer drug administration, and the use of fosaprepitant...Furthermore, the study suggested that in-administration care, such as administering the drug to alternating arms and using warm compresses for vasodilatory care to prevent vascular pain, as well as patient education, including self-monitoring where patients observe the condition of their blood vessels and report it during treatment, are useful. A comprehensive intervention approach combining these pre-treatment assessments, in-administration care, and patient education may be effective in suppressing vascular damage."

Clinical • Review • Breast Cancer • Oncology • Solid Tumor • Thrombosis • Vasculitis

GUIDELINE-CONGRUENT CARE FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING PROPHYLAXIS: HIGH DOSE METHOTREXATE (MASCC-ISOO 2026) - "The most frequent prophylactic antiemetics prescribed included aprepitant, fosaprepitant, palonosetron and ondansetron. Breakthrough antiemetics included cyclizine, olanzapine, metoclopramide, levomepromazine, lorazepam and subsequent doses of palonosetron and fosaprepitant or aprepitant at appropriate dosage intervals Conclusions Guideline concordant care is fundamental to optimising antiemetic prophylaxis, promoting a standardised prescribing approach that aligns with the emetic potential of the chemotherapy to ultimately improve quality of life. Locally, there is a need to improve assessment/documentation of patient's experiences of CINV and for prospective evaluation of local breakthrough practices."

CINV • Acute Lymphocytic Leukemia • Chemotherapy-Induced Nausea and Vomiting • Hematological Malignancies • Leukemia • Lymphoblastic Lymphoma • Lymphoma

Comparative Efficacy of Fosnetupitant and Fosaprepitant for Delayed Vomiting in Patients Receiving Irinotecan-Oxaliplatin Combination Chemotherapy: A Retrospective Propensity Score-Matched Study. (PubMed, Cancer Manag Res) - "With fosnetupitant, the time to first vomiting was longer (3/68 vs. 11/68, hazard ratio: 0.20, p=0.045), injection site reactions were fewer (0.0% vs. 19.1%, p0.05). Despite the retrospective design, possible calendar-time confounding, and limited number of events, our results suggest that fosnetupitant offers better control of long-delayed and overall vomiting and a favorable safety profile, compared with fosaprepitant, in patients receiving FOLFIRINOX/FOLFOXIRI regimens."

Journal • Retrospective data • Chemotherapy-Induced Nausea and Vomiting • Constipation • Gastroenterology • Gastrointestinal Disorder

Efficacy of NEPA for prevention of chemotherapy induced nausea and vomiting in head and neck cancer patients receiving cisplatin-based chemotherapy. (PubMed, Eur J Clin Pharmacol) - "Oral NEPA exhibited a superior anti-emetic efficacy than intravenous FOPA, as well as shorter hospitalization days for R/M HNSCC patients treated with cisplatin-based chemotherapy."

CINV • Journal • Chemotherapy-Induced Nausea and Vomiting • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Efficacy and safety of mixed formulation aprepitant and palonosetron (QLM2010) for prevention of cisplatin-based highly emetogenic chemotherapy-induced nausea and vomiting: A multicenter, randomized, double-blind, double-dummy, positive-controlled phase III study. (ASCO 2026) - P3 | "This study aimed to assess the efficacy and safety of QLM2010 plus dexamethasone (DEX) versus fosaprepitant (FAPR) combined with PALO and DEX for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). QLM2010 + DEX was non-inferior to FAPR + PALO + DEX for preventing CINV in cisplatin-based HEC patients and well tolerated, with the potential to reduce the impact of CINV on daily life. QLM2010 furnishes a novel, more convenient therapeutic alternative for the clinical management of CINV."

CINV • Clinical • P3 data • Chemotherapy-Induced Nausea and Vomiting • Solid Tumor

Dexamethasone-free antiemetic prophylaxis with olanzapine in children and adolescents receiving highly emetogenic chemotherapy: A multicenter, phase III non-inferiority randomized trial. (ASCO 2026) - "Patients were randomized 1:1 (single chemotherapy cycle) to receive dexamethasone, palonosetron, and fosaprepitant (DEX; standard-of-care) or olanzapine, palonosetron, and fosaprepitant (OLANZ; dexamethasone-free). A dexamethasone-free antiemetic regimen was non-inferior to standard dexamethasone-based prophylaxis for prevention of vomiting in children and adolescents receiving HEC. These findings support the use of olanzapine as an effective steroid-sparing alternative."

Clinical • Head-to-Head • P3 data • Chemotherapy-Induced Nausea and Vomiting • Oncology

Efficacy and Safety of Oral NEPA Versus Fosaprepitant Plus Palonosetron for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma: A Propensity-Score-Matched Retrospective Study. (PubMed, Cancers (Basel)) - " This single-center retrospective cohort study included patients with stage III-IVa NPC who received cisplatin-based induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) from January 2020 to October 2025...All patients also received olanzapine and dexamethasone... For patients with LA-NPC receiving highly emetogenic chemotherapy (HEC), oral NEPA appears to offer superior and sustained chemotherapy-induced nausea and vomiting (CINV) prophylaxi with a simplified administration schedule compared with the intravenous FosAPR plus PALO regimen. These findings warrant confirmation in prospective studies."

CINV • Journal • Retrospective data • Chemotherapy-Induced Nausea and Vomiting • Constipation • Gastroenterology • Gastrointestinal Disorder • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Fosnetupitant Versus Fosaprepitant for Delayed Vomiting Upon Irinotecan-Oxaliplatin Combination Chemotherapy for Pancreatic/Colorectal Cancer. (PubMed, Anticancer Res) - "The effectiveness of fosnetupitant may vary according to cancer type, suggesting the need to tailor antiemetic strategies for patients receiving irinotecan-oxaliplatin combination chemotherapy."

Clinical • Journal • Retrospective data • Chemotherapy-Induced Nausea and Vomiting • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Inhibition of the oncogenic GTPase dynamin-related protein 1 (DRP1) by the FDA-approved drug fosaprepitant: In silico, biophysical, and in vitro characterization of its anti-myeloma activity. (PubMed, Int J Biol Macromol) - "Consistent with inhibition of mitochondrial fission, fosaprepitant treatment in multiple myeloma (MM) cell lines induced mitochondrial hyperfusion, decreased cell viability and colony formation in a DRP1-dependent manner, and disrupted oxidative phosphorylation (OXPHOS), ultimately leading to mitochondrial dysfunction and apoptotic cell death. Overall, this study provides a robust platform for the identification of novel DRP1 inhibitors among FDA-approved compounds, highlighting fosaprepitant as a promising candidate for drug repurposing with anti-cancer potential."

FDA event • Journal • Preclinical • Hematological Malignancies • Metabolic Disorders • Multiple Myeloma • Oncology

Taxol Titration: "Balancing Safety and Tolerance" (ONS 2026) - "Oral premedications were replaced with IV formulations, a 30‑minute interval was enforced between premedication and paclitaxel initiation, and sequencing was standardized to diphenhydramine, dexamethasone, and famotidine before fosaprepitant. Discussion Despite ongoing challenges with hypersensitivity reactions to paclitaxel, this study demonstrates that nursing protocols can effectively reduce risks. Adherence to and continuous refinement of standardized infusion protocols are essential to maintaining improvements in patient safety and treatment outcomes."

Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting (clinicaltrials.gov) - P2/3 | N=200 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Jun 2026 ➔ Mar 2027 | Trial primary completion date: Jun 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date

Prevention of Postoperative Nausea and Vomiting with Intravenous Fosaprepitant in Patients Undergoing Bariatric Surgery (IARS-SOCCA 2026) - "The incidence of postoperative nausea was significantly lower in the fosaprepitant group than the group who received ondansetron and dexamethasone alone (17.7% vs. 39.7%, p<0.0001). Fosaprepitant, when given intravenously and in combination with the current standardized antiemetic regimen, was superior to the current standard alone in decreasing PONV and rescue antiemetic requirements. Unlike other antiemetics such as ondansetron and droperidol, fosaprepitant does not cause QT prolongation [3]. Since fosaprepitant use was associated with decreased rescue antiemetic requirements, it may indirectly reduce the risk of QT prolongation and related side effects ascribed to the other antiemetics, since patients would no longer require as many rescue doses to treat their PONV."

Bariatric surgery • Clinical • Surgery

An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Shanghai 6th People's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Chemotherapy-Induced Nausea and Vomiting

Root Cause Determination for Customer Complaint Biopharmaceutical Drug Product Samples with Abnormal Appearance. (PubMed, PDA J Pharm Sci Technol) - "The first vial had cyanocobalamin injectable (vitamin B12), the second vial had fosaprepitant (a non-Amgen drug), and the third vial had iron and saline solution (likely injectable anemia drug)...Following the identification of the likely sources of contamination, Amgen followed standard compliant-handling procedures, which may include communicating results back to complaints or health providers as appropriate. In conclusion, the pursuit of root cause determination is paramount in addressing customer complaints and ensuring the quality, safety, and efficacy of biopharmaceutical products."

Journal • Hematological Disorders

Novel inhibitors of BCRP and P-gp found among drugs used in the treatment of cancer (AACR 2026) - "Of the investigated compounds, cabozantinib (IC50 of 0.65 µM), midostaurin (0.69 µM), and entrectinib (5.8 µM) showed the strongest inhibition of BCRP. Nilotinib (1.0 µM), osimertinib (2.0 µM), and abemaciclib (2.4 µM) showed the strongest inhibition of the P-gp. The highest I2/IC50 ratios for BCRP were observed for mitotane (6190), cabozantinib (1730), and abiraterone (831). For P-gp, the highest I2/IC50 ratios were observed for nilotinib (2880), pazopanib (1580), and mitotane (1480)...The highest I1/IC50 ratios for BCRP were observed for doxorubicin (8.2), etoposide (2.8), and fosaprepitant (0.84). For P-gp, the highest I1/IC50 ratios were observed for amscarine (1.6), vinorelbine (0.55), and fosaprepitant (0.50)...Mechanistic static model for BCRP inhibitors suggested that cabozantinib, midostaurin, and apalutamide could almost fully inhibit intestinal BCRP, increasing the exposure to concomitantly administered rosuvastatin by 94%, 89%,..."

Breast Cancer • Oncology • Solid Tumor

Substance P regulates the immune response to promote coronavirus clearance in the airways (IMMUNOLOGY 2026) - "We thus asked whether Substance P plays a pro-viral or anti-viral role during coronavirus infection. Male C57BL/6 mice 8-12 weeks were infected with the mouse β-coronavirus MHV-A59 (1,000 PFU in 40 µL PBS delivered intranasally) and treated with the Substance P-receptor TacR1 antagonist fosaprepitant (i.p... Substance P receptor signaling plays a key early role in regulating the immune response to significantly improve viral clearance during coronavirus infection. Future experiments will examine the effects of blocking Substance P early vs. late in the infection cycle, and will determine how Substance P signaling affects immune cell function to promote viral clearance in infected animals."

Cough • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • TACR1

Comprehensive Evaluation of Risk Factors Associated with Ifosfamide-Induced Encephalopathy: A Real-World Retrospective Review (HOPA 2026) - "Several studies have identified risk factors associated with the development of IIE including hypoalbuminemia, increased serum creatinine, increased hemoglobin, poor performance status, prior cisplatin exposure, disease in the pelvis, ifosfamide infusion time, obesity, concomitant use of CYP3A4 or CYP2B6 inhibitors, cancer type, ifosfamide dose, ifosfamide formulation, and age...Secondary endpoints will include identifying an association between concomitant fosaprepitant/aprepitant use and IIE as well as comparing the incidence of neurotoxicity between the solution formulation of ifosfamide and reconstituted powder formulation... Pending Conclusion/ Pending"

Real-world • Real-world evidence • Retrospective data • Review • CNS Disorders • Genetic Disorders • Germ Cell Tumors • Hematological Malignancies • Lymphoma • Obesity • Sarcoma • Solid Tumor • CYP3A4

An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC (clinicaltrials.gov) - P4 | N=200 | Not yet recruiting | Sponsor: Shanghai 6th People's Hospital

New P4 trial • Chemotherapy-Induced Nausea and Vomiting

Comparison of Intraoperative Antiemetics for Pediatric Chiari Decompression (SCCM 2026) - "Aprepitant, whether used alone or in combination with ondansetron and/or dexamethasone, has been shown to outperform ondansetron for PONV...We hypothesized that patients who received intraoperative fosaprepitant (F) or aprepitant (A) would have decreased PONV and pain without significant difference in length of stay (LOS) compared to other perioperative antiemetic regimens. We performed a retrospective chart review of all patients who were admitted for and underwent FMD for Chiari malformation September 2014 through August 2024 at a quaternary pediatric hospital... Patients who received intraoperative F/A compared to those who did not had decreased odds of significant post-operative emesis. We discovered heterogeneity in post-operative pharmacotherapy regimens that may contribute to the lack of effect on pain. The standard addition of F/A to intraoperative care for FMD should be considered especially for patients at higher risk of PONV."

Clinical • Pediatrics